Lead Candidate

all catalysts(0)

nothing on the calendar yet

News(10)

• Kolon TissueGene cuts 37 US staffers after Phase 3 fail
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• BioMarin acquires experimental drug for rare bone disorder in $275M deal
  The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
  biopharma_dive · 2d ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 3d ago
• Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
  Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…
  fiercebiotech · 3d ago
• Abcuro gets $66M for Phase 3 in muscle-weakening condition
  Abcuro has collected $66 million a few months after saying its sole drug missed the mark in a muscle-weakening condition but had found hope in a subset of patients with less severe forms. CEO Alex ...
  endpoints · 6d ago
• MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
  ⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s d…
  endpoints · 6d ago
• Skye and Redx form new entity with $125M to advance fibrosis assets
  Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…
  fiercebiotech · 6d ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 8d ago
• After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
  Aardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find…
  fiercebiotech · 8d ago
• Epicrispr, Infinimmune snag combined $165M in VC cash
  Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
  biospace · 9d ago